Improvement in Glycemic Response After Bariatric Surgery

May 19, 2026 updated by: Weizmann Institute of Science
decipher the role of microbiota in glycemic response change after bariatric surgery

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Despite the vast knowledge linking the gut microbiome to metabolism and the glucose response, the relation still remains unclear. hopefully, a deep understanding of the mechanisms underlying metabolic improvement following bariatric surgery will make it possible to identify targets for pharmacological intervention, which will reduce the need for surgery and its risks.

Previous studies have characterized the microbiome after bariatric surgery, but most suffer from methodological limitations.

The current study has the potential to be innovative and make a significant contribution to understanding the mechanisms involved in early metabolic improvement after bariatric surgery.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Israel
      • Rehovot, Israel
        • Recruiting
        • Weizmann Institute of Science
        • Contact:
          • Avner Leshem, MD
      • Tel Aviv, Israel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

patients arriving at the outpatient unit at Tel Aviv Sourasky medical center

Description

Inclusion Criteria:

  • candidates of bariatric surgery or cholecystectomy
  • age 18-70
  • male/female

Exclusion Criteria:

  • previous bariatric surgery
  • type 1 diabetes
  • antibiotic treatment 3 months prior to the study
  • probiotic treatment 3 months prior to the study
  • chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders
  • any pathologic findings during endoscopy
  • participants who will suffer from a post-operation complication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
sleeve gastrectomy surgery
participants undergoing sleeve gastrectomy surgery for weight reduction
Procedure: sleeve gastrectomy surgery
participants undergoing sleeve gastrectomy surgery
gastric bypass surgery
participants undergoing gastric bypass surgery for weight reduction
Procedure: gastric bypass surgery
participants undergoing gastric bypass surgery
cholecystectomy
participants undergoing cholecystectomy
Procedure: control
cholecystectomy
Pancreatectomy
participants undergoing Pancreatectomy
Procedure: Pancreatectomy
Collecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycemic response
Time Frame: up to 4 years
The glycemic response will be measured by taking a blood test (glucose) after 12 hours fast and a second blood test (glucose) after an OGTT(oral glucose tolerance test) of 50 g glucose
up to 4 years
microbiota composition
Time Frame: up to 4 years
The microbiota composition will be assessed using the stool samples of the participants.
up to 4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Weizmann Institute of Science

Collaborators

Tel-Aviv Sourasky Medical Center

Investigators

  • Study Director: Avner Leshem, MD, Weizmann institute
  • Principal Investigator: Danit Dayan, MD, Souraski medical center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

February 10, 2022

First Submitted That Met QC Criteria

April 5, 2022

First Posted (Actual)

April 13, 2022

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0046-21-TLV

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bariatric Surgery

Clinical Trials on sleeve gastrectomy surgery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe